Categories
Change Password!
Reset Password!
Tegoprazan shows cardiovascular and gastrointestinal safety comparable to proton pump inhibitors in post-PCI patients receiving long-term antiplatelet therapy.
Tegoprazan exhibited similar cardiovascular (CV) and gastrointestinal (GI) safety outcomes to proton pump inhibitors (PPIs) in people with ischemic heart disease receiving long-term antiplatelet therapy after percutaneous coronary intervention (PCI), according to a real-world retrospective study.
Jin Lee and other researchers analyzed data from 604 patients treated with either tegoprazan (n=265) or PPIs (n=339) for more than 6 months following PCI. Volunteers were followed for a mean duration of 17 months. The key GI outcomes included symptomatic gastroduodenal ulcers and upper GI bleeding, while CV outcomes encompassed CV-related death, major adverse cardiac events (MACEs), target vessel revascularization, and nonfatal myocardial infarction (MI).
Overall, GI complications were infrequent in both groups. Only 7 patients experienced a GI event, with rates of 0.4% in the tegoprazan group and 1.8% in the PPI group; this difference did not reach statistical significance. Similarly, 12 patients developed MACEs during follow-up, corresponding to event rates of 1.1% with tegoprazan and 2.7% with PPIs. In subgroup analyses, target vessel revascularization occurred in 6 patients, including 2 patients (0.8%) receiving tegoprazan and 4 patients (1.2%) receiving PPIs.
The rates of nonfatal MI were also comparable between the two groups (0.8% with tegoprazan vs. 2.4% with PPIs). Deaths from CV-related causes were rare, occurring in 1 patient (0.4%) in the tegoprazan group and none in the PPI group, with no statistically significant difference. Thus, in those with ischemic heart disease undergoing PCI, tegoprazan provided GI protection and cardiovascular safety comparable to PPIs during prolonged antiplatelet therapy. With low rates of upper GI bleeding, MACEs, myocardial infarction, and target vessel revascularization, tegoprazan may represent a safe alternative acid-suppressive therapy in this high-risk population.
The Korean Journal of Helicobacter and Upper Gastrointestinal Research
Clinical Outcomes of Tegoprazan Versus Proton Pump Inhibitors in Patients Receiving Antiplatelet Therapy After Percutaneous Coronary Intervention: A Retrospective, Observational Study
Jin Lee et al.
Comments (0)